Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie’s launches win on value: report

Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie’s launches win on value: report
fkansteiner
Thu, 07/15/2021 – 11:22